31 Mar 2020 07:00
31 March 2020 07:00 BST
Â
Transactions by Persons Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
Â
AstraZeneca PLC (the Company) announced that, on 27 March 2020, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Performance Share Plan (AZPSP).
Â
The AZPSP award was granted on 27 March 2015 and was subject to a three-year performance period followed by a two-year holding period before vesting. Application of the performance measures specified at the time of grant resulted in 77% of the AZPSP award vesting and the remaining unvested part lapsing.
Â
Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below:
Â
PDMR | Ordinary Shares acquired under the AZPSP |
Pascal Soriot | 74,698 |
Marc Dunoyer | 19,429 |
Â
For tax purposes, the fair market value of an Ordinary Share at vest was 6882 pence, being the closing price on the last trading day preceding the vesting.
Â
Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.
Â
Â
1 Â | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) Â | Name | Pascal Soriot | ||||
2  | Reason for the notification  | |||||
a)  | Position/status  | Chief Executive Officer | ||||
b) Â | Initial notification /Amendment | Initial notification | ||||
3 Â | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) Â | Name | AstraZeneca PLC | ||||
b) Â | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
4i  | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)  | Description of the financial instrument, type of instrument  Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC   GB0009895292  | ||||
b)  | Nature of the transaction   | Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration. | ||||
c) Â | Price(s) and volume(s) Â | Â
 | ||||
d)  | Aggregated information  - Aggregated volume - Price | Not applicable - single transaction     | ||||
e)  | Date of the transaction  | 27 March 2020 | ||||
f)  | Place of the transaction  | Outside a trading venue | ||||
Â
Â
1 Â | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) Â | Name | Marc Dunoyer | ||||
2  | Reason for the notification  | |||||
a)  | Position/status  | Chief Financial Officer | ||||
b) Â | Initial notification /Amendment | Initial notification | ||||
3 Â | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) Â | Name | AstraZeneca PLC | ||||
b) Â | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
4i  | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)  | Description of the financial instrument, type of instrument  Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC   GB0009895292  | ||||
b)  | Nature of the transaction   | Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration. | ||||
c) Â | Price(s) and volume(s) Â | Â
 | ||||
d)  | Aggregated information  - Aggregated volume - Price | Not applicable - single transaction     | ||||
e)  | Date of the transaction  | 27 March 2020 | ||||
f)  | Place of the transaction  | Outside a trading venue | ||||
Â
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian KempCompany SecretaryAstraZeneca PLC
Astrazeneca (AZN)